FIELD: biotechnology.
SUBSTANCE: invention relates to a genetically modified rodent comprising a nucleotide sequence coding a human or humanized MHC molecule, which comprises at least a human peptide-binding cavity of a human leukocyte antigen (HLA) molecule or at least a human peptide-binding cavity thereof, and (non)-rearranged locus of human or humanized heavy chain of immunoglobulin and/or (non)-rearranged locus of human or humanized light chain of immunoglobulin, as well as to method of its production. Also disclosed is the use of said rodent in a method for producing a human or humanised antibody, in a method for producing a nucleic acid encoding a human variable domain of immunoglobulin, in a method of producing a cell which expresses a human immunoglobulin heavy chain variable domain and/or a human immunoglobulin light chain variable domain, as well as in a method for producing a human variable domain of immunoglobulin in vitro.
EFFECT: invention is effective for producing antigen-binding proteins against antigenic complexes of pMHC.
43 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED T-CELL MEDIATED IMMUNE RESPONSES IN NON-HUMAN ANIMALS | 2016 |
|
RU2732628C2 |
| DIVALENT BISPECIFIC CHIMERIC ANTIBODY COMPRISING HETERODIMER BASED ON MHC OR MHC-LIKE PROTEINS | 2021 |
|
RU2820683C2 |
| RODENTS HAVING CONSTRUCTED SECTION OF HEAVY CHAIN DIVERSITY | 2017 |
|
RU2763320C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| RECOMBINANT pMHC MOLECULES OF CLASS II | 2017 |
|
RU2777115C2 |
| NON-HUMAN ANIMALS EXPRESSING HUMANISED COMPLEX CD3 | 2015 |
|
RU2726446C2 |
| GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | 2012 |
|
RU2653433C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
| ANIMALS OTHER THAN HUMANS WITH CONSTRUCTED LOCUS OF LIGHT LAMBDA CHAIN OF IMMUNOGLOBULIN | 2017 |
|
RU2757665C2 |
